NTEC - Intec Pharma Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
0
0
0
0
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
35,163
35,402
24,295
10,749
Selling General and Administrative
8,617
7,926
5,117
3,072
Total Operating Expenses
43,780
43,328
29,439
13,846
Operating Income or Loss
-43,780
-43,328
-29,439
-13,846
Interest Expense
-
23
17
16
Total Other Income/Expenses Net
-
-941
106
324
Income Before Tax
-53,489
-43,440
-29,064
-13,362
Income Tax Expense
157
103
29
-
Income from Continuing Operations
-53,646
-43,543
-29,093
-13,362
Net Income
-53,646
-43,543
-29,093
-13,362
Net Income available to common shareholders
-53,646
-43,543
-29,093
-13,362
Reported EPS
Basic
-
-1.40
-1.65
-1.17
Diluted
-
-1.40
-1.65
-1.17
Weighted average shares outstanding
Basic
-
31,193
17,660
11,448
Diluted
-
31,193
17,660
11,448
EBITDA
-
-42,469
-28,218
-12,645